Medications for attention deficit hyperactivity disorder associated with increased risk of developing glaucoma.

Publication Date: 2024 May 06


Full Text Sources

Nature Publishing Group

Related Articles


Authors

Rami Darwich; Mahyar Etminan; Bonnie He; Brennan D Eadie

Abstract

OBJECTIVE

Attention deficit hyperactivity disorder (ADHD) therapies including atomoxetine, methylphenidate, and amphetamines are some of the most prescribed medications in North America. Due to their sympathomimetic action, these drugs are contraindicated in patients with a history of angle closure glaucoma (ACG). This study aims to determine the risk of ACG and open angle glaucoma (OAG) among users of these treatments.


Source

Eye (London, England)


Pub Types(s)

Journal Article


Language

English


PubMed ID

38710937